Skip to main content

Table 2 Number of references including specific preference-related term in the different guideline cases

From: The use of research evidence on patient preferences in pharmaceutical coverage decisions and clinical practice guideline development: exploratory study into current state of play and potential barriers

 

England & Wales GAD case

Scotland CHF case

Netherlands Prostate CA case

France CHF case

Germany Depression case

England & Wales RA case

Scotland RA case

Netherlands RA case

France RA case

Germany RA case

Total

Value

0

0

0

0

0

0

0

0

0

0

0

Utilities

1

0

0

0

0

0

0

2

0

1

4

Preference

3

1

5

0

0

2

1

0

0

0

12

View

1

0

1

0

0

1

0

0

0

0

3

Goal

0

0

0

0

0

0

0

0

0

0

0

Belief

3

0

0

0

0

1

0

0

0

0

4

Expectation

0

0

0

0

0

0

0

0

0

0

0

Experience

2

0

5

0

0

2

0

0

0

0

9

Satisfaction

0

0

0

0

0

3

0

1

0

0

4

Health related quality of life

3

1

3

0

1

9

0

2

2

1

22

Quality of life

4

3

18

0

3

4

0

2

0

1

35

Concern

0

1

2

0

0

0

0

0

0

0

3

Desire

0

0

0

0

0

0

0

0

0

0

0

Perspective

2

0

4

0

3

2

0

4

1

0

16

Attitude

0

0

0

0

1

0

0

0

0

0

1

Perception

1

1

0

0

0

1

0

0

0

0

3

Well being

1

1

1

0

1

4

0

1

1

1

11

Need (for)

5

0

9

0

4

2

0

0

0

0

20

Choice

0

0

0

0

0

2

0

0

0

1

3

PRO

0

0

0

0

0

1

0

0

0

3

4

  1. GAD: generalised anxiety disorder; CA: carcinoma; RA: Rheumatoid Arthritis.